Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PRPL NASDAQ:TDUP NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRPLPurple Innovation$0.52+4.5%$0.65$0.47▼$1.26$53.62M1.52409,595 shs533,767 shsTDUPThredUp$5.04+0.6%$3.93$3.08▼$12.28$636.46M2.072.55 million shs6.47 million shsTSHATaysha Gene Therapies$6.98+0.6%$5.04$1.85▼$7.30$1.99B1.252.82 million shs4.14 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRPLPurple Innovation+4.55%+5.12%-22.26%-23.10%-30.75%TDUPThredUp+0.60%+16.67%+37.70%+11.75%-23.17%TSHATaysha Gene Therapies+0.58%+11.32%+50.11%+58.28%+249.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRPLPurple Innovation$0.52+4.5%$0.65$0.47▼$1.26$53.62M1.52409,595 shs533,767 shsTDUPThredUp$5.04+0.6%$3.93$3.08▼$12.28$636.46M2.072.55 million shs6.47 million shsTSHATaysha Gene Therapies$6.98+0.6%$5.04$1.85▼$7.30$1.99B1.252.82 million shs4.14 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRPLPurple Innovation+4.55%+5.12%-22.26%-23.10%-30.75%TDUPThredUp+0.60%+16.67%+37.70%+11.75%-23.17%TSHATaysha Gene Therapies+0.58%+11.32%+50.11%+58.28%+249.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePRPLPurple Innovation 1.67Reduce$0.6526.16% UpsideTDUPThredUp 2.86Moderate Buy$9.1481.35% UpsideTSHATaysha Gene Therapies 3.00Buy$11.6466.71% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, TDUP, and PRPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.705/5/2026TDUPThredUp Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$10.00 ➝ $8.005/5/2026TDUPThredUp Telsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $7.004/29/2026PRPLPurple Innovation UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$0.85 ➝ $0.654/29/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.504/28/2026PRPLPurple Innovation KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Sector Weight4/21/2026PRPLPurple Innovation Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/6/2026TDUPThredUp TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.004/6/2026TSHATaysha Gene Therapies Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.004/1/2026PRPLPurple Innovation UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$1.00 ➝ $0.85(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPRPLPurple Innovation$468.73M0.12N/AN/A($0.55) per share-0.94TDUPThredUp$310.81M2.06N/AN/A$0.47 per share10.72TSHATaysha Gene Therapies$9.77M205.28N/AN/A$0.90 per share7.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePRPLPurple Innovation-$51.41M-$0.58N/AN/AN/A-13.65%N/A-12.25%N/ATDUPThredUp-$20.21M-$0.16N/AN/AN/A-6.68%-36.11%-12.53%N/ATSHATaysha Gene Therapies-$109M-$0.34N/AN/AN/AN/A-56.64%-38.53%N/ALatest TSHA, TDUP, and PRPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A5/4/2026Q1 2026TDUPThredUp-$0.05-$0.05N/A-$0.05$80.17 million$81.67 million4/28/2026Q4 2025PRPLPurple Innovation-$0.13-$0.13N/A-$0.28$100.92 million$95.73 million3/31/2026Q4 2025PRPLPurple Innovation-$0.04-$0.02+$0.02-$0.03$139.81 million$140.69 million3/19/2026Q4 2025TSHATaysha Gene Therapies-$0.11-$0.08+$0.03-$0.08$1.89 million$5.49 million3/2/2026Q4 2025TDUPThredUp-$0.04-$0.04N/A-$0.04$77.17 million$79.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPRPLPurple InnovationN/AN/AN/AN/AN/ATDUPThredUpN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPRPLPurple InnovationN/A1.240.62TDUPThredUp0.300.950.91TSHATaysha Gene Therapies0.2012.2312.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPRPLPurple Innovation88.41%TDUPThredUp89.08%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipPRPLPurple Innovation53.90%TDUPThredUp23.10%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePRPLPurple Innovation1,100108.80 million50.16 millionOptionableTDUPThredUp2,132127.04 million97.69 millionOptionableTSHATaysha Gene Therapies180287.34 million276.48 millionOptionableTSHA, TDUP, and PRPL HeadlinesRecent News About These CompaniesTaysha Gene Therapies Q1 Earnings Call Highlights1 hour ago | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsMay 6 at 3:27 PM | marketbeat.comTaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6 at 8:00 AM | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Here's What HappenedMay 5 at 3:39 PM | marketbeat.comTaysha Gene Therapies (TSHA) to Release Earnings on WednesdayMay 2, 2026 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6April 29, 2026 | globenewswire.comHas Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?April 28, 2026 | finance.yahoo.comTaysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual MeetingApril 27, 2026 | quiverquant.comQTaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingApril 27, 2026 | globenewswire.comTaysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay RevealedApril 22, 2026 | quiverquant.comQTaysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High - Should You Buy?April 22, 2026 | marketbeat.comTaysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago LevelsApril 22, 2026 | insidermonkey.comTaysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA)April 16, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Sets New 12-Month High - Still a Buy?April 16, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 9% - Should You Buy?April 15, 2026 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by BrokeragesApril 15, 2026 | marketbeat.comThis is why Taysha Gene Therapies, Inc. (TSHA) is one of the best healthcare penny stocks to buyApril 14, 2026 | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sells $892,000.00 in StockApril 14, 2026 | insidertrades.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 200,000 SharesApril 13, 2026 | marketbeat.comAberdeen Group plc Purchases Shares of 1,021,063 Taysha Gene Therapies, Inc. $TSHAApril 9, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, TDUP, and PRPL Company DescriptionsPurple Innovation NASDAQ:PRPL$0.52 +0.02 (+4.55%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$0.55 +0.03 (+6.56%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Purple Innovation, Inc. designs and manufactures sleep and other products in the United States and internationally. The company offers mattresses, pillows, cushions, bases, sheets, platforms, adjustable bases, mattress protectors, foundations, blankets, duvets, duvet covers, seat cushions, and pet beds under the Purple brand. It markets and sells its products through its e-commerce online channels, retail brick-and-mortar wholesale partners, third-party online retailers, and Purple showrooms, as well as through its website, Purple.com. The company was founded in 2010 and is headquartered in Lehi, Utah.ThredUp NASDAQ:TDUP$5.04 +0.03 (+0.60%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$5.04 0.00 (-0.06%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California.Taysha Gene Therapies NASDAQ:TSHA$6.98 +0.04 (+0.58%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$7.08 +0.11 (+1.50%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
